Which claims in this pitch survive independent verification?
Venture, growth, and public-market investors underwriting healthcare-AI companies.
What we can answer for you
- Disclosed funding and institutional investor counts, sourced and dated.
- Deployment claims separated into independently corroborated versus vendor-asserted.
- Material events — partnerships, clearances, consolidation — on a dated timeline.
- Forecast questions with predeclared resolution rules and a published Brier score.
What we will not tell you
- This is not investment advice and carries no view on any security.
- We do not estimate revenue, ARR, or valuation. Where a vendor asserts a number, we label it as asserted.
The Strategic lens — Capital position, momentum, platform trajectory. This reorders the same dimensions every audience sees. It never creates a separate score.
- 1market durability35%
- 2deployment traction25%
- 3evidence strength20%
- 4interoperability10%
- 5trust governance10%
3 of 39 products currently pass the documentary gate. 40 of 142 claims are source-checked. This is not an audience-specific recommendation. The gate is one global evidence test — it does not change by role, and neither does this list. What the lens above changes is which dimensions we weight when you read a record.
What a product must clear to appear here
- Every claim resolves to a live source that the gate re-fetches, with the class and date recorded.
- Median evidence age is inside the freshness bar — Current (≤45d) or Aging (46–120d). Historical evidence cannot carry a decision.
- The product maps to an evaluated buying scenario, so it has peers to be compared against.
- No critical dimension is left entirely unevidenced.
Almost all 36 exclusions are staleness, not product quality. Every excluded product keeps a full profile and states its own reason.
See all 39 products, including the excluded → · Exclusion reasons, broken down →